DRRX [NASD]
DURECT Corporation
Index- P/E- EPS (ttm)-0.16 Insider Own0.20% Shs Outstand227.69M Perf Week4.99%
Market Cap97.55M Forward P/E- EPS next Y-0.16 Insider Trans- Shs Float224.52M Perf Month-11.40%
Income-37.00M PEG- EPS next Q-0.05 Inst Own52.30% Short Float5.88% Perf Quarter-37.21%
Sales13.70M P/S7.12 EPS this Y-124.20% Inst Trans-0.09% Short Ratio15.65 Perf Half Y-59.18%
Book/sh0.21 P/B1.98 EPS next Y15.80% ROA-39.30% Target Price5.67 Perf Year-74.76%
Cash/sh0.27 P/C1.52 EPS next 5Y15.00% ROE-60.90% 52W Range0.36 - 1.85 Perf YTD-57.76%
Dividend- P/FCF- EPS past 5Y9.10% ROI-43.70% 52W High-77.43% Beta1.46
Dividend %- Quick Ratio7.60 Sales past 5Y-0.10% Gross Margin85.80% 52W Low15.63% ATR0.05
Employees78 Current Ratio7.80 Sales Q/Q-13.60% Oper. Margin- RSI (14)47.61 Volatility12.31% 12.47%
OptionableYes Debt/Eq0.00 EPS Q/Q-2.20% Profit Margin- Rel Volume1.10 Prev Close0.39
ShortableYes LT Debt/Eq0.44 EarningsMay 04 AMC Payout- Avg Volume843.34K Price0.42
Recom1.70 SMA200.90% SMA50-15.16% SMA200-52.97% Volume926,024 Change5.74%
Oct-30-20Initiated Chardan Capital Markets Buy $7
Oct-12-20Initiated ROTH Capital Buy
Jul-31-20Initiated Oppenheimer Outperform $7
Jan-31-20Initiated B. Riley FBR Buy $5
Nov-18-19Resumed Cantor Fitzgerald Overweight
Sep-06-19Initiated Cantor Fitzgerald Overweight $5
Mar-06-18Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-20-17Reiterated Laidlaw Buy $3 → $2
Oct-20-17Downgrade Stifel Buy → Hold $3 → $0.90
Oct-20-17Downgrade H.C. Wainwright Buy → Neutral
Jul-12-17Upgrade Stifel Hold → Buy $1.25 → $3
Feb-28-17Resumed H.C. Wainwright Buy $3
Apr-25-16Initiated Rodman & Renshaw Buy $4
May-01-15Reiterated Stifel Buy $1.50 → $2.50
May-01-15Reiterated Cantor Fitzgerald Buy $2.50 → $3
Mar-25-13Initiated Stifel Buy $3
Nov-01-12Downgrade C.K. Cooper Buy → Hold $3
Aug-17-12Initiated C.K. Cooper Buy $3
Jun-23-09Initiated Caris & Company Buy $5
Mar-26-09Initiated Wedbush Morgan Hold
May-18-22 01:53PM  
May-08-22 08:19AM  
May-04-22 06:25PM  
04:05PM  
Apr-27-22 04:15PM  
Mar-24-22 09:30AM  
Mar-23-22 04:15PM  
01:29PM  
Mar-09-22 04:30PM  
Mar-07-22 05:25PM  
04:05PM  
Mar-01-22 08:30AM  
Feb-28-22 04:30PM  
09:15AM  
Jan-13-22 10:00AM  
Jan-06-22 04:05PM  
Dec-22-21 07:30AM  
05:45AM  
Dec-14-21 09:00AM  
Nov-29-21 09:00AM  
Nov-12-21 09:00AM  
Nov-10-21 09:00AM  
Nov-08-21 09:00AM  
Nov-07-21 07:45AM  
Nov-02-21 06:15PM  
04:05PM  
Oct-26-21 09:00AM  
Oct-25-21 03:01PM  
Oct-07-21 09:00AM  
Sep-23-21 09:00AM  
Sep-15-21 09:00AM  
Sep-07-21 09:00AM  
Aug-09-21 05:29AM  
Jul-29-21 07:25PM  
04:05PM  
Jul-22-21 08:30AM  
Jul-14-21 04:30PM  
Jun-25-21 09:37AM  
Jun-23-21 09:00AM  
Jun-09-21 09:00AM  
May-04-21 07:45PM  
04:05PM  
02:30PM  
Apr-27-21 08:30AM  
Mar-09-21 09:00AM  
Mar-04-21 05:31PM  
05:25PM  
02:30PM  
Mar-03-21 06:02PM  
Feb-04-21 09:18AM  
Feb-03-21 04:01PM  
Feb-02-21 08:28AM  
08:01AM  
Jan-25-21 08:30AM  
Jan-05-21 08:30AM  
Jan-04-21 08:30AM  
Dec-21-20 08:30AM  
Dec-16-20 08:30AM  
Dec-09-20 01:33PM  
Dec-07-20 11:15AM  
Nov-13-20 09:00AM  
Nov-10-20 08:30AM  
Nov-02-20 11:31PM  
06:15PM  
04:05PM  
04:02PM  
02:30PM  
07:35AM  
Oct-27-20 08:30AM  
Oct-26-20 04:30PM  
12:31PM  
Oct-05-20 08:30AM  
Sep-30-20 04:53PM  
Sep-23-20 08:30AM  
Sep-22-20 08:30AM  
Sep-10-20 08:30AM  
Aug-27-20 08:30AM  
Aug-26-20 04:30PM  
Aug-05-20 03:31PM  
08:30AM  
Aug-04-20 01:00AM  
Aug-03-20 06:35PM  
04:05PM  
Jul-28-20 08:30AM  
Jul-07-20 07:35AM  
Jul-01-20 08:30AM  
Jun-29-20 09:00AM  
08:30AM  
Jun-26-20 05:15PM  
10:37AM  
Jun-11-20 02:45PM  
May-28-20 09:00AM  
May-26-20 08:30AM  
May-20-20 10:04AM  
May-12-20 03:00PM  
02:20PM  
May-11-20 06:55PM  
04:05PM  
May-04-20 05:00PM  
Apr-28-20 12:33PM  
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Robertson Judith J.DirectorMay 26Buy0.3965,00025,597265,000May 27 05:31 PM
AZAB MOHAMMADDirectorMay 24Buy0.3930,00011,63860,000May 25 08:03 PM
Farfel Gail MDirectorMay 18Buy0.4129,91112,201100,000May 18 08:35 PM
AZAB MOHAMMADDirectorMay 17Buy0.4220,0008,40730,000May 18 08:05 PM
Farfel Gail MDirectorMay 16Buy0.3925,3009,81170,089May 18 08:35 PM
AZAB MOHAMMADDirectorMay 16Buy0.3810,0003,76710,000May 18 08:05 PM
Farfel Gail MDirectorMay 13Buy0.409,2503,70044,789May 13 09:07 PM
Farfel Gail MDirectorMay 12Buy0.391,50058535,539May 13 09:07 PM
Farfel Gail MDirectorMay 11Buy0.409,9503,97334,039May 13 09:07 PM
Farfel Gail MDirectorMay 10Buy0.412,33995024,089May 12 08:32 PM
Farfel Gail MDirectorMay 10Buy0.404,2501,67921,750May 10 09:12 PM
Farfel Gail MDirectorMay 09Buy0.3917,5006,90617,500May 10 09:12 PM
Robertson Judith J.DirectorMar 14Buy0.59200,000118,000200,000Mar 16 01:41 PM
BENITO SIMON XDirectorDec 07Buy1.0220,00020,360105,000Dec 09 01:35 PM